Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$24.65 USD

24.65
132,670,919

+0.36 (1.48%)

Updated Oct 31, 2025 04:00 PM ET

After-Market: $24.67 +0.02 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.16%
3Hold10.10%
4Sell5.63%
5Strong Sell2.84%
S&P50011.45%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 32% (165 out of 243)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

MRK's ADC Candidate Gets FDA Breakthrough Therapy Tag for Lung Cancer

by Zacks Equity Research

Merck's ifinatamab deruxtecan wins FDA Breakthrough Therapy status for treating adults with extensive-stage small cell lung cancer.

Kinjel Shah headshot

Pfizer Oncology Drugs Drive Sales in Q2: Will the Trend Continue?

by Kinjel Shah

Pfizer's oncology portfolio, boosted by Seagen and strong drug sales, fuels Q2 growth and positions the company for future cancer treatment gains.

Zacks Equity Research

AstraZeneca Rides Oncology Momentum With Blockbuster and New Drugs

by Zacks Equity Research

AstraZeneca's oncology sales jump 18% in second-quarter 2025, fueled by key drugs and new launches like Truqap and Datroway.

Kinjel Shah headshot

PFE New & Acquired Drugs Back 1H Top-Line Growth: Will the Trend Last?

by Kinjel Shah

Pfizer's new and acquired drugs record sales of $4.7B in H1 as COVID-products related volatility eases.

Ekta Bagri headshot

Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth?

by Ekta Bagri

Exelixis reports strong phase III results for zanzalintinib in metastatic colorectal cancer, raising hopes beyond Cabometyx.

Zacks Equity Research

SMMT Q2 Loss Wider Than Expected, Ivonescimab Studies in Focus

by Zacks Equity Research

Summit Therapeutics posts wider-than-expected second-quarter loss as ivonescimab trials advance in multiple lung cancer settings.

Santanu Roy headshot

The Zacks Analyst Blog Highlights Pfizer, Novo Nordisk and Eli Lilly

by Santanu Roy

Pfizer beats Q2 estimates with rising oncology sales, new drug launches, and strong Seagen-driven portfolio growth.

Kinjel Shah headshot

Should Pfizer Stock Be in Your Portfolio After Solid Q2 Results?

by Kinjel Shah

Pfizer posts strong Q2 earnings and raises EPS outlook, with oncology growth and new drugs offsetting looming headwinds.

Zacks Equity Research

Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Sridatri Sarkar headshot

Abbott's EPD Growth Beats Market Trends: Here's How to Play the Stock

by Sridatri Sarkar

Abbott outpaces market trends as EPD sales surge, fueled by double-digit growth, biosimilar approvals and strong product demand.

Zacks Equity Research

Company News for Aug 6, 2025

by Zacks Equity Research

Companies in The News Are: PFE,MPC,CMI,GLDD

Ekta Bagri headshot

BMY Stock Trades Near 52-Week Low: Time to Buy or Sell?

by Ekta Bagri

BMY trims earnings outlook despite revenue beat and upbeat drug sales, sending shares to a 52-week low before a rebound. We recommend investors to stay on the sidelines for now.

Zacks Equity Research

Pfizer Q2 Earnings Beat Estimates, Oncology Drives Top-Line Growth

by Zacks Equity Research

PFE posts strong Q2 results with earnings up 30% and revenues up 10% year over year, fueled by rising oncology sales and cost cuts.

Zacks Equity Research

Trade Deficit Narrowed More Than Expected

by Zacks Equity Research

Trade Deficit Narrowed More Than Expected

Mark Vickery headshot

Pre-markets Slightly Up on Mostly Good Q2 Earnings

by Mark Vickery

Q2 earnings reports are overall posting favorable results, including this morning ahead of the open.

Zacks Equity Research

Here's What Key Metrics Tell Us About Pfizer (PFE) Q2 Earnings

by Zacks Equity Research

While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Ekta Bagri headshot

Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock?

by Ekta Bagri

EXEL rides on strong Cabometyx demand in RCC and NET, but Q2 sales miss and rising competition cloud the outlook.

Zacks Equity Research

Pfizer (PFE) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Pfizer (PFE) delivered earnings and revenue surprises of +34.48% and +6.35%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Mark Vickery headshot

Selloff? What Selloff? Monday Market Rebound

by Mark Vickery

Palantir is way up after reporting Q2 results Monday afternoon, while HIMS and VRTX are way off highs.

Zacks Equity Research

Viatris Poised to Report Q2 Earnings: What's in Store for the Stock?

by Zacks Equity Research

VTRS braces for Q2 results as branded drug growth in Europe and China offsets generic headwinds in North America.

Zacks Equity Research

Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?

by Zacks Equity Research

Let's look at five pharma and biotech companies, PFE, LLY, AMGN, GILD and NVO, which are scheduled to release their second-quarter 2025 results this week.

Zacks Equity Research

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Zacks Equity Research

MRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales View

by Zacks Equity Research

MRNA tops Q2 estimates with a narrower loss and revenue beat, but the stock slips after trimming 2025 sales guidance.

Kinjel Shah headshot

Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q2 Earnings

by Kinjel Shah

PFE eyes Q2 earnings beat as strength in Vyndaqel and Padcev is expected to offset declines from Eliquis, Ibrance and Prevnar.

Zacks Equity Research

Pfizer (PFE) Dips More Than Broader Market: What You Should Know

by Zacks Equity Research

In the most recent trading session, Pfizer (PFE) closed at $23.27, indicating a -2.29% shift from the previous trading day.